On August 23, Gelunhui announced that in order to promote the long-term development of the company and fully leverage the resource advantages of professional investment institutions to better complete the industrial layout and enhance comprehensive competitiveness, while not affecting the company's daily operation and development and effectively controlling investment risks, the company plans to sign the "Changzhou Langya Guoxing Medical Investment Partnership Enterprise (Limited Partnership) Partnership Agreement" (hereinafter referred to as the "Partnership Agreement") with Peking Langzi Hanyue Asset Management Co., Ltd. (hereinafter referred to as "Langzi Hanyue"), Changzhou Guoxing Investment Management Co., Ltd. (hereinafter referred to as "Guoxing Investment"), Changzhou Zhonglou Science and Technology Venture Capital Partnership Enterprise (Limited Partnership) (hereinafter referred to as "Zhonglou Science and Technology"), Changzhou Xinhui Entrepreneurship Investment Co., Ltd. (hereinafter referred to as "Changzhou Xinhui"), and Beihai Fenghao Entrepreneurship Investment Co., Ltd. (hereinafter referred to as "Beihai Fenghao"), and jointly contribute to the establishment of Changzhou Langya Guoxing Medical Investment Partnership Enterprise (Limited Partnership) (tentative name, the final name shall be subject to the approval of the industrial and commercial registration, hereinafter referred to as "Partnership Enterprise" or "Fund").

At the time of the establishment of the fund, the total amount of capital contribution subscribed by all partners is 100 million yuan. The company plans to subscribe for a capital contribution of 25 million yuan with its own funds as a limited partner, accounting for 25% of the total contribution.

The partnership enterprise mainly invests in the equity of unlisted companies in the growth stage and a small number of unlisted companies in the start-up stage, focusing on areas including biomedical, high-end medical devices, or related service industries, including but not limited to: (1) instruments related to surgery/high-value consumables; (2) upstream key raw materials or manufacturing platforms related to innovative medical devices driven by breakthroughs in underlying technologies such as synthetic biology and new materials or processes; (3) materials and equipment related to upstream bottleneck of life sciences.